\-\ Texto\\:\\ \ \(0\)\
\-\ on\\ examination\\:\\ slight\\ exophthalmos\\ with\\ downward\\ displacement\\ of\\ the\\ re\\,\\ lid\\ ptosis\\,\\ upper\\ lid\\ poorly\\ mobile\\ infiltrative\\ lesion\\ fixed\\ to\\ adjacent\\ tissues\\,\\ no\\ circumscribed\\ mass\\.\ \(0\)\
\-\ high\\-dose\\ chemotherapy\\ \\(vad\\,\\ vincristine\\,\\ adriamycin\\,\\ dexamethasone\\)\\,\\ followed\\ by\\ autologous\\ stem\\ cell\\ transplantation\\,\\ are\\ the\\ treatment\\ modalities\\ scheduled\\ for\\ this\\ patient\\.\ \(0\)\
\-\ followup\\ ocular\\ examination\\:\\ decreased\\ proptosis\\,\\ improved\\ motility\ \(0\)\
\-\ \\â\\€\\¢\\ a\\-b\\-scan\\:\\ large\\,\\ poorly\\ defined\\,\\ hypoechogenic\\ tumour\\ of\\ the\\ superior\\ extraconal\\ right\\ orbit\\,\\ with\\ medium\\-low\\ internal\\ reflectivity\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ contrast\\-enhanced\\ ct\\ scan\\ and\\ mri\\:\\ bulky\\ mass\\ \\(30x21x34\\ mm\\)\\ of\\ the\\ right\\ orbit\\ causing\\ downward\\ displacement\\ of\\ the\\ globe\\ and\\ medial\\ displacement\\ of\\ the\\ superior\\ rectus\\ muscle\\ and\\ optic\\ nerve\\.\\ the\\ lesion\\ showed\\ focal\\ erosions\\ of\\ the\\ orbital\\ roof\\,\\ without\\ extension\\ into\\ the\\ brain\\ parenchyma\\.\\ \ \(0\)\
\-\ \\â\\€\\¢\\ skull\\ x\\-rays\\ assessed\\ changes\\ in\\ the\\ bone\\ structure\\ with\\ multiple\\ punched\\-out\\ lytic\\ lesions\\,\\ without\\ sclerosis\\ or\\ periosteal\\ reaction\\.\\ \ \(0\)\
\-\ ocullar\\ pathology\\:\\ immunohistochemical\\ stains\\ positive\\ for\\ monoclonal\\ light\\ kappa\\ chains\\,\\ cd\\ 138\\ \\(specific\\ marker\\ for\\ plasma\\ cells\\)\\ proliferation\\ index\\ \\(ki\\-67\\)\\ 20\\%\\.\ \(0\)\
\-\ non\\-secretory\\ myeloma\ \(0\)\
\-\ \\â\\€\\¢\\ plasmocytoma\ \(1\)\
\-\ \\â\\€\\¢\\ metastatic\\ carcinoma\ \(1\)\
\-\ \\â\\€\\¢\\ lymphoma\\ and\\ sarcoma\\.\ \(1\)\
\-\ 62\\-year\\-old\\ woman\\ with\\ a\\ 5\\-month\\ history\\ of\\ slowly\\ progressive\\ swelling\\ and\\ ptosis\\ of\\ the\\ right\\ upper\\ eyelid\\.\\ \ \(1\)\
\-\ pmh\\:\\ systemic\\ hypertension\\ \ \(0\)\
\-\ va\\:\\ 20\\/25\\ in\\ the\\ affected\\ eye\\ \ \(0\)\
\-\ \\ \\ \\ \\ \\ \\ \\ 20\\/22\\ in\\ the\\ contralateral\\ eye\\.\\ \ \(1\)\
\-\ iop\\:\\ 14\\ mmhg\\ in\\ both\\ eyes\\.\\ \ \(0\)\
\-\ ocular\\ motility\\:\\ restricted\\ in\\ all\\ directions\\ of\\ gaze\\.\\ \ \(0\)\
\-\ pupillary\\ light\\ reaction\\:\\ preserved\\.\\ \ \(0\)\
\-\ fundus\\ examination\\:\\ mild\\ optic\\ nerve\\ head\\ elevation\\ and\\ retinal\\ venous\\ congestion\\.\ \(0\)\
\-\ presented\\ by\\ maria\\ antonietta\\ blasi\\,\\ m\\.d\\.\\ at\\ the\\ vzs\\-eops\\ combined\\ meeting\\ in\\ new\\ york\\ in\\ 2006\\.\ \(0\)\
\-\ malignant\\ plasma\\ cell\\ tumours\\ divided\\ according\\ to\\ site\\ of\\ origin\\:\\ multicentric\\,\\ such\\ as\\ multiple\\ myeloma\\ \\(mm\\)\\,\\ or\\ localized\\,\\ originating\\ at\\ bone\\ \\(solitary\\ plasmocytoma\\ of\\ bone\\)\\ or\\ from\\ soft\\ tissue\\ \\(extramedullary\\ plasmocytoma\\)\\.\\ \ \(0\)\
\-\ mm\\:\\ 15\\%\\ of\\ all\\ haematological\\ malignancies\\,\\ characterized\\ by\\ overproduction\\ of\\ a\\ serum\\ monoclonal\\ protein\\,\\ skeletal\\ destruction\\ with\\ osteolytic\\ lesions\\.\\ \ \(0\)\
\-\ incidence\\:\\ about\\ 5\\.0\\ and\\ about\\ 4\\.2\\ per\\ 100\\.000\\ person\\-years\\,\\ in\\ men\\ and\\ women\\ respectively\\.\\ \ \(0\)\
\-\ median\\ age\\ at\\ diagnosis\\:\\ 68\\ years\\ in\\ males\\ and\\ 70\\ in\\ females\\.\\ \ \(0\)\
\-\ risk\\ factors\\:\\ exposure\\ to\\ specific\\ agents\\ \\(pesticides\\,\\ petroleum\\ product\\,\\ asbestos\\,\\ rubber\\,\\ plastic\\ and\\ wood\\ products\\)\\,\\ high\\ dose\\ radiation\\,\\ long\\-standing\\,\\ chronic\\ infection\\ or\\ chronic\\ antigenic\\ stimulation\\,\\ viruses\\.\\ \ \(0\)\
\-\ the\\ most\\ common\\ sites\\ are\\ in\\ marrow\\ areas\\ of\\ most\\ active\\ haematopoiesis\\,\\ including\\,\\ in\\ order\\ of\\ frequency\\,\\ the\\ vertebrae\\,\\ ribs\\,\\ skull\\,\\ pelvis\\,\\ femur\\,\\ clavicle\\ and\\ scapula\\.\ \(0\)\
\-\ diagnosis\\:\\ a\\ constellation\\ of\\ radiological\\,\\ clinical\\,\\ laboratory\\ and\\ pathological\\ findings\\ are\\ combined\\ to\\ provide\\ diagnostic\\ criteria\\ for\\ mm\ \(0\)\
\-\ treatment\\:\\ high\\-dose\\ chemotherapy\\ with\\ haemopoietic\\ stem\\-cell\\ support\\,\\ suitable\\ for\\ patients\\ younger\\ than\\ 65\\ years\\ \\(only\\ about\\ a\\ third\\ of\\ all\\ myeloma\\ patients\\)\\.\\ \ \(0\)\
\-\ mm\\ is\\ still\\ an\\ incurable\\ neoplasm\\ with\\ a\\ median\\ survival\\ of\\ about\\ 4\\-5\\ years\\ obtained\\ with\\ high\\-dose\\ chemotherapy\\.\\ \ \(0\)\
\-\ its\\ incidence\\ shows\\ a\\ sharp\\ increase\\ of\\ about\\ 3\\%\\ per\\ year\\ and\\ the\\ global\\ mortality\\ rate\\ remains\\ stable\\.\\ \\ \ \(0\)\
\-\ about\\ 4\\%\\ of\\ mm\\ are\\ non\\-secretory\\:\\ plasma\\ cells\\ synthesise\\ but\\ do\\ not\\ secrete\\ ig\\ molecules\\,\\ leading\\ to\\ the\\ absence\\ of\\ a\\ m\\-component\\ \\(paraprotein\\)\\.\\ due\\ to\\ the\\ lack\\ of\\ serum\\ or\\ urine\\ monoclonal\\ ig\\,\\ the\\ diagnosis\\ can\\ be\\ missed\\.\\ \ \(0\)\
\-\ in\\ our\\ patient\\,\\ a\\ non\\-secretory\\ variant\\ of\\ mm\\ was\\ diagnosed\\:\\ \ \(0\)\
\-\ laboratory\\ tests\\ within\\ the\\ normal\\ range\\,\ \(1\)\
\-\ bone\\ marrow\\ sample\\ showed\\ \\<\\ 30\\%\\ of\\ plasma\\ cells\\ and\\ \ \(1\)\
\-\ lytic\\ bone\\ lesions\\ observed\\ only\\ on\\ the\\ skull\\.\\ \ \(1\)\
\-\ the\\ diagnosis\\ could\\ be\\ made\\ because\\ of\\ the\\ orbital\\ involvement\\,\\ which\\ was\\ the\\ first\\ manifestation\\ of\\ the\\ disease\\.\\ \ \(0\)\
\-\ \\ \ \(1082074\)\
\-\ as\\ solitary\\ plasmacytoma\\ will\\ progress\\ to\\ multiple\\ myeloma\\,\\ a\\ doubt\\ still\\ remains\\ about\\ the\\ onset\\ of\\ the\\ orbital\\ lesion\\.\\ \ \(0\)\
\-\ the\\ pathological\\ process\\ could\\ have\\ started\\ in\\ the\\ orbital\\ wall\\ as\\ solitary\\ plasmocytoma\\ of\\ the\\ bone\\,\\ although\\ the\\ orbital\\ bone\\ is\\ very\\ unusual\\ as\\ site\\ of\\ origin\\,\\ \ \(0\)\
\-\ or\\ it\\ could\\ have\\ developed\\ from\\ the\\ orbital\\ soft\\ tissue\\ as\\ extramedullary\\ plasmocytoma\\ and\\ have\\ filled\\ the\\ orbital\\ superior\\ extraconal\\ space\\.\\ \ \(1\)\
\-\ such\\ distinction\\ is\\ not\\ possible\\ now\\ that\\ the\\ disease\\ is\\ systemic\\ and\\ the\\ presence\\ of\\ a\\ non\\-secretory\\ form\\ of\\ myeloma\\ makes\\ the\\ clinical\\ picture\\ rather\\ confused\\.\\ \ \(0\)\
\-\ this\\ case\\ deserves\\ attention\\ for\\ the\\ uncommon\\ modality\\ of\\ presentation\\ of\\ a\\ rare\\ disease\\,\\ the\\ non\\-secretory\\ mm\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ non\\-secretory\\:\\ 0\\.057021464579343456\ \(0\)\
\-\ plasmocytoma\\:\\ 0\\.057021464579343456\ \(0\)\
\-\ orbital\\:\\ 0\\.03670557752157981\ \(0\)\
\-\ mm\\:\\ 0\\.03251948415829243\ \(0\)\
\-\ myeloma\\:\\ 0\\.03211753442597956\ \(0\)\
\-\ plasma\\:\\ 0\\.029862851157790818\ \(0\)\
\-\ about\\:\\ 0\\.029829757493828928\ \(0\)\
\-\ \\:\\:\\ 0\\.029243850349046963\ \(0\)\
\-\ high\\-dose\\:\\ 0\\.026660834184648843\ \(0\)\
\-\ monoclonal\\:\\ 0\\.02568548711499461\ \(0\)\
\-\ bone\\:\\ 0\\.019229033337928962\ \(0\)\
\-\ ig\\:\\ 0\\.018172726920409943\ \(0\)\
\-\ \\,\\:\\ 0\\.017510353526344592\ \(0\)\
\-\ extraconal\\:\\ 0\\.017123658076663075\ \(0\)\
\-\ solitary\\:\\ 0\\.01645850237566539\ \(0\)\
\-\ lid\\:\\ 0\\.015980494422642277\ \(0\)\
\-\ motility\\:\\ 0\\.015980494422642277\ \(0\)\
\-\ ptosis\\:\\ 0\\.015330263042872792\ \(0\)\
\-\ extramedullary\\:\\ 0\\.014931425578895409\ \(0\)\
\-\ downward\\:\\ 0\\.014378840584592538\ \(0\)\
\-\ displacement\\:\\ 0\\.014213040735324912\ \(0\)\
\-\ skull\\:\\ 0\\.014124328685870643\ \(0\)\
\-\ ocular\\:\\ 0\\.013396978691436256\ \(0\)\
\-\ cells\\:\\ 0\\.013297981995407493\ \(0\)\
\-\ pathological\\:\\ 0\\.012902657250911782\ \(0\)\
\-\ \\%\\:\\ 0\\.012893409012587372\ \(0\)\
\-\ median\\:\\ 0\\.01279254181903909\ \(0\)\
\-\ could\\:\\ 0\\.012235024361567473\ \(0\)\
\-\ combined\\:\\ 0\\.012215197572430525\ \(0\)\
\-\ \\â\\€\\¢\\:\\ 0\\.012163112690265624\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.011887241080753681\ \(0\)\
\-\ remains\\:\\ 0\\.011503416743853757\ \(0\)\
\-\ vad\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ a\\-b\\-scan\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ medium\\-low\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ reflectivity\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ 30x21x34\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ ocullar\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ ki\\-67\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ 20\\/22\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ maria\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ antonietta\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ blasi\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ vzs\\-eops\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ haematological\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ 100\\.000\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ person\\-years\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ antigenic\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ viruses\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ haematopoiesis\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ haemopoietic\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ incurable\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ synthesise\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ m\\-component\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ paraprotein\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ deserves\\:\\ 0\\.011404292915868692\ \(0\)\
\-\ orbit\\:\\ 0\\.011137539243078006\ \(0\)\
\-\ poorly\\:\\ 0\\.010792050517011969\ \(0\)\
\-\ serum\\:\\ 0\\.010670557675905188\ \(0\)\
\-\ superior\\:\\ 0\\.010590208397364262\ \(0\)\
\-\ systemic\\:\\ 0\\.010577310750981004\ \(0\)\
\-\ still\\:\\ 0\\.010531917970512932\ \(0\)\
\-\ 138\\:\\ 0\\.010507595398973548\ \(0\)\
\-\ 62\\-year\\-old\\:\\ 0\\.010507595398973548\ \(0\)\
\-\ 5\\-month\\:\\ 0\\.010507595398973548\ \(0\)\
\-\ overproduction\\:\\ 0\\.010507595398973548\ \(0\)\
\-\ pesticides\\:\\ 0\\.010507595398973548\ \(0\)\
\-\ petroleum\\:\\ 0\\.010507595398973548\ \(0\)\
\-\ rubber\\:\\ 0\\.010507595398973548\ \(0\)\
\-\ stem\\-cell\\:\\ 0\\.010507595398973548\ \(0\)\
\-\ light\\:\\ 0\\.01031618288916998\ \(0\)\
\-\ examination\\:\\ 0\\.010309533126033242\ \(0\)\
\-\ optic\\:\\ 0\\.010234685691086225\ \(0\)\
\-\ diagnosis\\:\\ 0\\.010153786963934904\ \(0\)\
\-\ origin\\:\\ 0\\.010136296569251196\ \(0\)\
\-\ incidence\\:\\ 0\\.010136296569251196\ \(0\)\
\-\ reaction\\:\\ 0\\.010041512266069358\ \(0\)\
\-\ tumour\\:\\ 0\\.009983060977100115\ \(0\)\
\-\ lytic\\:\\ 0\\.009896729203590587\ \(0\)\
\-\ years\\:\\ 0\\.009738330415336931\ \(0\)\
\-\ marrow\\:\\ 0\\.009726449207291566\ \(0\)\
\-\ per\\:\\ 0\\.009677476348596822\ \(0\)\
\-\ punched\\-out\\:\\ 0\\.009610897882078407\ \(0\)\
\-\ kappa\\:\\ 0\\.009610897882078407\ \(0\)\
\-\ secrete\\:\\ 0\\.009610897882078407\ \(0\)\
\-\ molecules\\:\\ 0\\.009610897882078407\ \(0\)\
\-\ all\\:\\ 0\\.009380039415645372\ \(0\)\
\-\ \\(\\:\\ 0\\.009344912370554471\ \(0\)\
\-\ site\\:\\ 0\\.009344144209287718\ \(0\)\
\-\ re\\:\\ 0\\.009322225758774125\ \(0\)\
\-\ adriamycin\\:\\ 0\\.009322225758774125\ \(0\)\
\-\ hypoechogenic\\:\\ 0\\.009322225758774125\ \(0\)\
\-\ 20\\/25\\:\\ 0\\.009322225758774125\ \(0\)\
\-\ eye\\:\\ 0\\.009274022786835477\ \(0\)\
\-\ \\)\\:\\ 0\\.00923075927701559\ \(0\)\
\-\ specific\\:\\ 0\\.00913923595143211\ \(0\)\
\-\ dexamethasone\\:\\ 0\\.009086363460204971\ \(0\)\
\-\ chains\\:\\ 0\\.009086363460204971\ \(0\)\
\-\ wood\\:\\ 0\\.009086363460204971\ \(0\)\
\-\ suitable\\:\\ 0\\.009086363460204971\ \(0\)\
\-\ immunohistochemical\\:\\ 0\\.008886944728216281\ \(0\)\
\-\ iop\\:\\ 0\\.008886944728216281\ \(0\)\
\-\ doubt\\:\\ 0\\.008886944728216281\ \(0\)\
\-\ lesions\\:\\ 0\\.008877983853857494\ \(0\)\
\-\ meeting\\:\\ 0\\.008714200365183264\ \(0\)\
\-\ multicentric\\:\\ 0\\.008714200365183264\ \(0\)\
\-\ cd\\:\\ 0\\.008561829038331538\ \(0\)\
\-\ 2006\\.\\:\\ 0\\.008561829038331538\ \(0\)\
\-\ va\\:\\ 0\\.008425528241878982\ \(0\)\
\-\ tumours\\:\\ 0\\.008425528241878982\ \(0\)\
\-\ as\\:\\ 0\\.008360785937219456\ \(0\)\
\-\ directions\\:\\ 0\\.008302229173568083\ \(0\)\
\-\ m\\.d\\:\\ 0\\.008302229173568083\ \(0\)\
\-\ autologous\\:\\ 0\\.00818966594330983\ \(0\)\
\-\ pupillary\\:\\ 0\\.00818966594330983\ \(0\)\
\-\ sample\\:\\ 0\\.00818966594330983\ \(0\)\
\-\ distinction\\:\\ 0\\.00818966594330983\ \(0\)\
\-\ laboratory\\:\\ 0\\.008147714711136006\ \(0\)\
\-\ exophthalmos\\:\\ 0\\.008086117809191412\ \(0\)\
\-\ 5\\.0\\:\\ 0\\.008086117809191412\ \(0\)\
\-\ bulky\\:\\ 0\\.007990247211321138\ \(0\)\
\-\ nerve\\:\\ 0\\.007966225424287985\ \(0\)\
\-\ eyelid\\:\\ 0\\.007900993820005548\ \(0\)\
\-\ or\\:\\ 0\\.00777378589105077\ \(0\)\
\-\ assessed\\:\\ 0\\.007665131521436396\ \(0\)\
\-\ product\\:\\ 0\\.007665131521436396\ \(0\)\
\-\ long\\-standing\\:\\ 0\\.007665131521436396\ \(0\)\
\-\ in\\:\\ 0\\.007632032628672145\ \(0\)\
\-\ 4\\.2\\:\\ 0\\.007595186862613271\ \(0\)\
\-\ plastic\\:\\ 0\\.007595186862613271\ \(0\)\
\-\ stains\\:\\ 0\\.007528830724983839\ \(0\)\
\-\ gaze\\:\\ 0\\.007528830724983839\ \(0\)\
\-\ plasmacytoma\\:\\ 0\\.007528830724983839\ \(0\)\
\-\ vincristine\\:\\ 0\\.0074657127894477045\ \(0\)\
\-\ osteolytic\\:\\ 0\\.0074657127894477045\ \(0\)\
\-\ retinal\\:\\ 0\\.00740553165667294\ \(0\)\
\-\ transplantation\\:\\ 0\\.007348026142351033\ \(0\)\
\-\ asbestos\\:\\ 0\\.007348026142351033\ \(0\)\
\-\ 4\\-5\\:\\ 0\\.007348026142351033\ \(0\)\
\-\ global\\:\\ 0\\.007348026142351033\ \(0\)\
\-\ scapula\\:\\ 0\\.007292968426414686\ \(0\)\
\-\ showed\\:\\ 0\\.007249167575481752\ \(0\)\
\-\ york\\:\\ 0\\.007240158601679557\ \(0\)\
\-\ marker\\:\\ 0\\.007189420292296269\ \(0\)\
\-\ have\\:\\ 0\\.007181519062218985\ \(0\)\
\-\ constellation\\:\\ 0\\.007140597099562962\ \(0\)\
\-\ manifestation\\:\\ 0\\.007140597099562962\ \(0\)\
\-\ malignancies\\:\\ 0\\.007048153420414003\ \(0\)\
\-\ missed\\:\\ 0\\.007004296303110405\ \(0\)\
\-\ multiple\\:\\ 0\\.006985016831096775\ \(0\)\
\-\ the\\:\\ 0\\.006975060935887976\ \(0\)\
\-\ divided\\:\\ 0\\.006961877386133703\ \(0\)\
\-\ such\\:\\ 0\\.00691159842132174\ \(0\)\
\-\ stimulation\\:\\ 0\\.006880997234799506\ \(0\)\
\-\ attention\\:\\ 0\\.006804877571121714\ \(0\)\
\-\ clinical\\:\\ 0\\.006802871410261331\ \(0\)\
\-\ lesion\\:\\ 0\\.006755065560157004\ \(0\)\
\-\ mmhg\\:\\ 0\\.006732989018528168\ \(0\)\
\-\ roof\\:\\ 0\\.006698489345718128\ \(0\)\
\-\ x\\-rays\\:\\ 0\\.006698489345718128\ \(0\)\
\-\ clavicle\\:\\ 0\\.006698489345718128\ \(0\)\
\-\ proliferation\\:\\ 0\\.006664885870422836\ \(0\)\
\-\ only\\:\\ 0\\.006647895623505655\ \(0\)\
\-\ modalities\\:\\ 0\\.006632133208088696\ \(0\)\
\-\ originating\\:\\ 0\\.0066001893366910615\ \(0\)\
\-\ stem\\:\\ 0\\.006569015272552561\ \(0\)\
\-\ products\\:\\ 0\\.006569015272552561\ \(0\)\
\-\ preserved\\:\\ 0\\.0065385747843116895\ \(0\)\
\-\ confused\\:\\ 0\\.0065385747843116895\ \(0\)\
\-\ agents\\:\\ 0\\.006479761881236972\ \(0\)\
\-\ picture\\:\\ 0\\.006479761881236972\ \(0\)\
\-\ younger\\:\\ 0\\.006451328625455891\ \(0\)\
\-\ globe\\:\\ 0\\.006423506885195912\ \(0\)\
\-\ index\\:\\ 0\\.006423506885195912\ \(0\)\
\-\ fixed\\:\\ 0\\.006396270909519545\ \(0\)\
\-\ rectus\\:\\ 0\\.006396270909519545\ \(0\)\
\-\ fundus\\:\\ 0\\.006396270909519545\ \(0\)\
\-\ radiological\\:\\ 0\\.006396270909519545\ \(0\)\
\-\ respectively\\:\\ 0\\.0063695965405638705\ \(0\)\
\-\ males\\:\\ 0\\.0063695965405638705\ \(0\)\
\-\ vertebrae\\:\\ 0\\.0063695965405638705\ \(0\)\
\-\ infiltrative\\:\\ 0\\.006343461084784415\ \(0\)\
\-\ mobile\\:\\ 0\\.006292722775401127\ \(0\)\
\-\ 68\\:\\ 0\\.006268080867288975\ \(0\)\
\-\ men\\:\\ 0\\.006243899582667819\ \(0\)\
\-\ progress\\:\\ 0\\.006243899582667819\ \(0\)\
\-\ chronic\\:\\ 0\\.006227657523692109\ \(0\)\
\-\ contrast\\-enhanced\\:\\ 0\\.006196852177530853\ \(0\)\
\-\ provide\\:\\ 0\\.006196852177530853\ \(0\)\
\-\ proptosis\\:\\ 0\\.006173954923844694\ \(0\)\
\-\ according\\:\\ 0\\.006151455903518861\ \(0\)\
\-\ females\\:\\ 0\\.006151455903518861\ \(0\)\
\-\ erosions\\:\\ 0\\.006129341500725458\ \(0\)\
\-\ makes\\:\\ 0\\.006129341500725458\ \(0\)\
\-\ contralateral\\:\\ 0\\.006107598786215263\ \(0\)\
\-\ modality\\:\\ 0\\.00606517986923856\ \(0\)\
\-\ criteria\\:\\ 0\\.006044480850679128\ \(0\)\
\-\ are\\:\\ 0\\.0060278078785490396\ \(0\)\
\-\ congestion\\:\\ 0\\.0060241078144978345\ \(0\)\
\-\ sites\\:\\ 0\\.0060241078144978345\ \(0\)\
\-\ mortality\\:\\ 0\\.0060241078144978345\ \(0\)\
\-\ slowly\\:\\ 0\\.006004050652096845\ \(0\)\
\-\ sharp\\:\\ 0\\.005984299717904363\ \(0\)\
\-\ cell\\:\\ 0\\.0059721622550620605\ \(0\)\
\-\ ribs\\:\\ 0\\.005964845801520741\ \(0\)\
\-\ eyes\\:\\ 0\\.0059456801019280615\ \(0\)\
\-\ support\\:\\ 0\\.0059267942035824564\ \(0\)\
\-\ survival\\:\\ 0\\.0059267942035824564\ \(0\)\
\-\ frequency\\:\\ 0\\.0058362915016330254\ \(0\)\
\-\ dose\\:\\ 0\\.005784880985915672\ \(0\)\
\-\ tests\\:\\ 0\\.005784880985915672\ \(0\)\
\-\ exposure\\:\\ 0\\.0057517083719268785\ \(0\)\
\-\ patients\\:\\ 0\\.0057220558845175315\ \(0\)\
\-\ protein\\:\\ 0\\.005672317755657418\ \(0\)\
\-\ for\\:\\ 0\\.005659312926075409\ \(0\)\
\-\ a\\:\\ 0\\.005643722923679966\ \(0\)\
\-\ scheduled\\:\\ 0\\.005568769621539003\ \(0\)\
\-\ order\\:\\ 0\\.005540645447365126\ \(0\)\
\-\ by\\:\\ 0\\.005522138046228492\ \(0\)\
\-\ pmh\\:\\ 0\\.0054995733926244015\ \(0\)\
\-\ characterized\\:\\ 0\\.0054995733926244015\ \(0\)\
\-\ elevation\\:\\ 0\\.00545976529603093\ \(0\)\
\-\ skeletal\\:\\ 0\\.00545976529603093\ \(0\)\
\-\ destruction\\:\\ 0\\.00545976529603093\ \(0\)\
\-\ disease\\:\\ 0\\.005420714907693548\ \(0\)\
\-\ uncommon\\:\\ 0\\.005408524496425437\ \(0\)\
\-\ 65\\:\\ 0\\.0053960252585059845\ \(0\)\
\-\ soft\\:\\ 0\\.005384027849918629\ \(0\)\
\-\ localized\\:\\ 0\\.005383645632353138\ \(0\)\
\-\ women\\:\\ 0\\.0053713833503938315\ \(0\)\
\-\ unusual\\:\\ 0\\.005347202065772676\ \(0\)\
\-\ urine\\:\\ 0\\.005335278837952594\ \(0\)\
\-\ upper\\:\\ 0\\.005335266508069129\ \(0\)\
\-\ 70\\:\\ 0\\.0053117570797595924\ \(0\)\
\-\ observed\\:\\ 0\\.00530015466063571\ \(0\)\
\-\ leading\\:\\ 0\\.005288655375490502\ \(0\)\
\-\ followup\\:\\ 0\\.005277257406949551\ \(0\)\
\-\ improved\\:\\ 0\\.005265958985256466\ \(0\)\
\-\ variant\\:\\ 0\\.005265958985256466\ \(0\)\
\-\ our\\:\\ 0\\.005254758386623718\ \(0\)\
\-\ rather\\:\\ 0\\.005254758386623718\ \(0\)\
\-\ periosteal\\:\\ 0\\.005243653931654259\ \(0\)\
\-\ tissue\\:\\ 0\\.005240417046449143\ \(0\)\
\-\ without\\:\\ 0\\.005205726174277258\ \(0\)\
\-\ slight\\:\\ 0\\.005200165431267474\ \(0\)\
\-\ form\\:\\ 0\\.005168482352343417\ \(0\)\
\-\ filled\\:\\ 0\\.005137556710876983\ \(0\)\
\-\ most\\:\\ 0\\.00510436000447109\ \(0\)\
\-\ restricted\\:\\ 0\\.005087602201009221\ \(0\)\
\-\ lack\\:\\ 0\\.005030096686687314\ \(0\)\
\-\ structure\\:\\ 0\\.005020756133034679\ \(0\)\
\-\ of\\:\\ 0\\.004973642207417359\ \(0\)\
\-\ factors\\:\\ 0\\.004966086263319436\ \(0\)\
\-\ started\\:\\ 0\\.00493088242952269\ \(0\)\
\-\ sarcoma\\:\\ 0\\.004922229146015838\ \(0\)\
\-\ circumscribed\\:\\ 0\\.00491363335983386\ \(0\)\
\-\ 14\\:\\ 0\\.004871490836632551\ \(0\)\
\-\ do\\:\\ 0\\.004798930077704939\ \(0\)\
\-\ affected\\:\\ 0\\.0047833436113192025\ \(0\)\
\-\ causing\\:\\ 0\\.004775620238762276\ \(0\)\
\-\ femur\\:\\ 0\\.004775620238762276\ \(0\)\
\-\ parenchyma\\:\\ 0\\.0047081095619568815\ \(0\)\
\-\ defined\\:\\ 0\\.004657933591665605\ \(0\)\
\-\ increase\\:\\ 0\\.004637011393417738\ \(0\)\
\-\ absence\\:\\ 0\\.004596155543417352\ \(0\)\
\-\ stable\\:\\ 0\\.00455655058116689\ \(0\)\
\-\ tissues\\:\\ 0\\.004537193695427288\ \(0\)\
\-\ pathology\\:\\ 0\\.004524448163159485\ \(0\)\
\-\ at\\:\\ 0\\.004493259325349158\ \(0\)\
\-\ treatment\\:\\ 0\\.004475076221477069\ \(0\)\
\-\ range\\:\\ 0\\.004450504548877533\ \(0\)\
\-\ third\\:\\ 0\\.0044326606651358316\ \(0\)\
\-\ 15\\:\\ 0\\.004409245346062587\ \(0\)\
\-\ made\\:\\ 0\\.004403457143740568\ \(0\)\
\-\ diagnostic\\:\\ 0\\.004380559890054408\ \(0\)\
\-\ progressive\\:\\ 0\\.004369261468361324\ \(0\)\
\-\ hypertension\\:\\ 0\\.004358060869728574\ \(0\)\
\-\ rate\\:\\ 0\\.004308824696605231\ \(0\)\
\-\ rare\\:\\ 0\\.0042928204381284555\ \(0\)\
\-\ \\<\\:\\ 0\\.004266578948902705\ \(0\)\
\-\ process\\:\\ 0\\.0042562296052195536\ \(0\)\
\-\ developed\\:\\ 0\\.0042562296052195536\ \(0\)\
\-\ 30\\:\\ 0\\.004251085816888842\ \(0\)\
\-\ active\\:\\ 0\\.00422064532864797\ \(0\)\
\-\ its\\:\\ 0\\.004171450767730455\ \(0\)\
\-\ diagnosed\\:\\ 0\\.004064935519786554\ \(0\)\
\-\ involvement\\:\\ 0\\.004051667084900151\ \(0\)\
\-\ pelvis\\:\\ 0\\.004016935842938718\ \(0\)\
\-\ venous\\:\\ 0\\.004012659273553854\ \(0\)\
\-\ very\\:\\ 0\\.004012659273553854\ \(0\)\
\-\ presence\\:\\ 0\\.004012659273553854\ \(0\)\
\-\ risk\\:\\ 0\\.0040041483148241745\ \(0\)\
\-\ malignant\\:\\ 0\\.003995692983673094\ \(0\)\
\-\ including\\:\\ 0\\.003991485952125387\ \(0\)\
\-\ 20\\:\\ 0\\.0039747933197374075\ \(0\)\
\-\ muscle\\:\\ 0\\.0039706536008102785\ \(0\)\
\-\ sclerosis\\:\\ 0\\.0039706536008102785\ \(0\)\
\-\ extension\\:\\ 0\\.003946089678113394\ \(0\)\
\-\ obtained\\:\\ 0\\.003929969082462926\ \(0\)\
\-\ because\\:\\ 0\\.003867423436721925\ \(0\)\
\-\ to\\:\\ 0\\.0038673696754216087\ \(0\)\
\-\ new\\:\\ 0\\.00385224835291146\ \(0\)\
\-\ presentation\\:\\ 0\\.003807762787181219\ \(0\)\
\-\ now\\:\\ 0\\.0037789334924988975\ \(0\)\
\-\ neoplasm\\:\\ 0\\.0037647562430943447\ \(0\)\
\-\ although\\:\\ 0\\.0037334143345104836\ \(0\)\
\-\ and\\:\\ 0\\.003725930260951482\ \(0\)\
\-\ possible\\:\\ 0\\.0037231335302510635\ \(0\)\
\-\ areas\\:\\ 0\\.003719724671728418\ \(0\)\
\-\ first\\:\\ 0\\.0037095516620774286\ \(0\)\
\-\ followed\\:\\ 0\\.003706178358834116\ \(0\)\
\-\ internal\\:\\ 0\\.003706178358834116\ \(0\)\
\-\ swelling\\:\\ 0\\.0036828083622006892\ \(0\)\
\-\ space\\:\\ 0\\.003656606736192283\ \(0\)\
\-\ radiation\\:\\ 0\\.0036277506462643423\ \(0\)\
\-\ positive\\:\\ 0\\.0035871741142097244\ \(0\)\
\-\ medial\\:\\ 0\\.0035359631482406884\ \(0\)\
\-\ right\\:\\ 0\\.003499217499781695\ \(0\)\
\-\ adjacent\\:\\ 0\\.0034952603417002163\ \(0\)\
\-\ onset\\:\\ 0\\.0034895488045603496\ \(0\)\
\-\ will\\:\\ 0\\.0034585782902705592\ \(0\)\
\-\ be\\:\\ 0\\.0034094611212003344\ \(0\)\
\-\ age\\:\\ 0\\.0033646964107947046\ \(0\)\
\-\ brain\\:\\ 0\\.0033264573393308695\ \(0\)\
\-\ decreased\\:\\ 0\\.003286877623188305\ \(0\)\
\-\ from\\:\\ 0\\.0032766771362334086\ \(0\)\
\-\ infection\\:\\ 0\\.0032134755162649513\ \(0\)\
\-\ wall\\:\\ 0\\.003202016973141975\ \(0\)\
\-\ not\\:\\ 0\\.00319487366556775\ \(0\)\
\-\ changes\\:\\ 0\\.003168238002891411\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0031593772760536687\ \(0\)\
\-\ focal\\:\\ 0\\.003157171544810352\ \(0\)\
\-\ head\\:\\ 0\\.0031353186423983136\ \(0\)\
\-\ carcinoma\\:\\ 0\\.0031331535187786117\ \(0\)\
\-\ scan\\:\\ 0\\.003094788435230244\ \(0\)\
\-\ 4\\:\\ 0\\.0030801706405938494\ \(0\)\
\-\ mass\\:\\ 0\\.003074931453939365\ \(0\)\
\-\ shows\\:\\ 0\\.003039293272611745\ \(0\)\
\-\ high\\:\\ 0\\.0030252859781071356\ \(0\)\
\-\ presented\\:\\ 0\\.0030133992691104908\ \(0\)\
\-\ due\\:\\ 0\\.0029499057606116943\ \(0\)\
\-\ mild\\:\\ 0\\.0029110652702860765\ \(0\)\
\-\ is\\:\\ 0\\.002909654739377623\ \(0\)\
\-\ than\\:\\ 0\\.002896570316841234\ \(0\)\
\-\ common\\:\\ 0\\.0028929718136564003\ \(0\)\
\-\ both\\:\\ 0\\.0028230271548332748\ \(0\)\
\-\ metastatic\\:\\ 0\\.0027828064729832993\ \(0\)\
\-\ into\\:\\ 0\\.0026304351461315743\ \(0\)\
\-\ 3\\:\\ 0\\.002588584122518163\ \(0\)\
\-\ was\\:\\ 0\\.0025569922955075985\ \(0\)\
\-\ woman\\:\\ 0\\.002553561380968831\ \(0\)\
\-\ mri\\:\\ 0\\.002539813525115938\ \(0\)\
\-\ can\\:\\ 0\\.00250740278456542\ \(0\)\
\-\ this\\:\\ 0\\.0024867715739046135\ \(0\)\
\-\ it\\:\\ 0\\.0024849267587749246\ \(0\)\
\-\ case\\:\\ 0\\.0024185050877972456\ \(0\)\
\-\ large\\:\\ 0\\.002417260584516274\ \(0\)\
\-\ but\\:\\ 0\\.0023577015537303205\ \(0\)\
\-\ findings\\:\\ 0\\.0023529585197800255\ \(0\)\
\-\ patient\\:\\ 0\\.0022162792520475758\ \(0\)\
\-\ within\\:\\ 0\\.0021088375270195106\ \(0\)\
\-\ which\\:\\ 0\\.0020635764388648756\ \(0\)\
\-\ that\\:\\ 0\\.0019094187950308196\ \(0\)\
\-\ on\\:\\ 0\\.0018729392299234881\ \(0\)\
\-\ normal\\:\\ 0\\.001733004469080338\ \(0\)\
\-\ ct\\:\\ 0\\.00154631779222774\ \(0\)\
\-\ an\\:\\ 0\\.0015286738218431176\ \(0\)\
\-\ history\\:\\ 0\\.00152679759082417\ \(0\)\
\-\ \\.\\:\\ 0\\.0014695797608215795\ \(0\)\
\-\ year\\:\\ 0\\.0012368761568860476\ \(0\)\
\-\ with\\:\\ 0\\.0012109099724697517\ \(0\)\
\-\ no\\:\\ 0\\.0011131230927604167\ \(0\)\
